Whether you're looking for an angel investor, a growth advisor, or just want to connect — I'm always open to great ideas.
Get in TouchAI, startups & growth insights. No spam.
The fundraising playbook from 2019–2021 is dead. Zero interest rate policy is gone, valuations have compressed 40–60% from peak, and VCs are deploying capital at roughly half the pace they were three years ago. But here's the thing — this is actually a better environment for founders who know what they're doing. There are more funding instruments available today than at any point in startup history. Revenue-based financing has matured into a real asset class. Rolling SAFEs let you close checks as you go. Angel syndicates have democratized access to institutional-quality deal flow. And non-dilutive grant programs are collectively worth billions globally.
This article is my attempt to map the entire landscape as it exists in 2026 — not as it existed in the ZIRP era — and give you a decision framework for choosing the right path for your specific situation.
Let me give you the honest picture first, because too many founders are still operating on assumptions baked in during the free-money era.
From 2010 to 2022, the Federal Reserve maintained near-zero interest rates for most of that stretch. This did something unusual to the venture capital market: it made everything else boring. Institutional limited partners — the pension funds, endowments, and family offices that fund VCs — were starved for yield. The bond market was paying them essentially nothing. So they poured money into alternatives, including venture capital. VC funds ballooned. Tiger Global was writing term sheets in 48 hours. SoftBank was investing at 100x revenue multiples. Valuations at seed were routinely hitting $10M–$20M for companies with no revenue and a pitch deck.
Then the Fed raised rates from 0.25% to 5.25% between March 2022 and July 2023. The most aggressive hiking cycle in 40 years.
What happened to venture:
But here is the part that gets less coverage: VC dry powder is actually near all-time highs. Funds raised during 2020–2022 still have capital to deploy. The problem is not money — it's conviction. Partners who wrote term sheets in 24 hours during ZIRP are now spending 12 weeks doing diligence on deals that would have closed in two. The posture has shifted from "we can't miss this" to "we need to be right."
What this means for you as a founder:
First, your fundraising timeline is longer than you think. Budget 6 months minimum, not 3. Second, the bar for what "traction" means has moved. In 2021, $50K MRR with 30% month-over-month growth was a good seed story. Today it's table stakes for many funds. Third, the valuation anchor has reset. If you're a pre-product company trying to raise at $15M cap, you will get more rejections than you expect. The market for pre-revenue companies has compressed significantly.
None of this means fundraising is impossible. It means the skills that matter have changed. The best founders I know who raised in 2024–2025 did it with clear unit economics, a believable path to profitability, and a specific thesis about why they win that didn't depend on the market being irrational. That's actually a more honest version of venture than what we had before.
There's also a structural shift happening at the bottom of the market. A new generation of funding instruments has emerged to serve companies that either can't or don't want to optimize for VC returns. Revenue-based financing, rolling SAFEs, angel syndicates, and non-dilutive grants have collectively become a serious alternative to the traditional VC path for a large swath of startups. I'll cover each of those in depth.
Venture capital is a specific financial instrument with a specific goal: returning 3x–10x on a fund within a 10-year window. To do that at fund scale, a VC needs their winners to return 50x–100x or more. That math means they're looking for companies that can become very large, very fast, in winner-take-all or winner-take-most markets.
This is not a subtle point. Most startups should not raise VC.
Venture capital is the right tool when all of the following are true:
Your market is large and winner-take-all. If you're building in a $500M addressable market and you can realistically capture 10% of it, that's a $50M revenue company. Good business. Not a VC business. VC is built for $10B+ markets where network effects, data moats, or switching costs make the leader hard to dislodge. Payments, enterprise software, marketplace platforms, consumer social — these are historically VC categories. Niche SaaS for a specific vertical? Often not.
Your growth requires capital before revenue. Building infrastructure, training proprietary AI models, manufacturing physical hardware, acquiring users at scale in a two-sided marketplace — these are capital-intensive bets where you need to spend now to win later. If your product can generate revenue from day one with modest investment, you probably don't need VC.
You want to go very big or go home. VC-backed companies are expected to grow fast or die trying. The fund model doesn't work if you're optimizing for a good outcome — it needs great outcomes. If you'd be satisfied building a $5M–$20M annual revenue business with strong margins and paying yourself well, VC is probably the wrong structure. You will spend your time managing investor expectations in a direction that doesn't match your personal goals.
You're in a category where speed is the moat. First-mover advantage is often overstated, but in certain markets — particularly where regulatory capture, network effects, or switching costs compound quickly — being 18 months ahead matters enormously. If you're in one of those markets and a competitor is funded, you may need to race. VC is the only instrument that lets you throw capital at the problem at that velocity.
When VC is genuinely the wrong choice:
If you do go the VC route, go in knowing the game. You are signing up for hypergrowth or failure. The middle outcomes — the good-but-not-great exits — have gotten harder to make happen because every term sheet you sign narrows your exit options. Liquidation preferences, anti-dilution, board control, drag-along rights — all of these constrain you in ways that only matter when you're not crushing it.
The good news: VC has gotten more competitive at the fund level, which has created better terms for founders. With the proliferation of micro-VCs and solo GPs, you have more options than ever at the seed stage. Many of these smaller funds take smaller stakes, write smaller checks, and offer more founder-friendly terms precisely because they're competing with each other for the best deals.
Revenue-based financing (RBF) is one of the most misunderstood instruments in startup finance, and it's genuinely useful for the right type of company.
Here's the basic mechanics: An RBF provider gives you capital upfront in exchange for a percentage of your monthly revenue until you've repaid a fixed multiple of the original advance — typically 1.3x–1.5x. No equity. No board seat. No personal guarantee (usually). No fixed monthly payment that crushes you in a down month.
Example: You take $500K from an RBF provider at a 1.4x cap with 8% revenue share. You repay $700K total. If your monthly revenue is $200K, you're paying $16K/month and you're done in about 44 months. If revenue doubles to $400K, you pay $32K/month and you're done in about 22 months. If revenue drops to $100K, you pay $8K/month and the repayment period stretches accordingly. The payment is always proportional to revenue — it breathes with the business.
The major players:
Typical RBF terms at a glance:
| Parameter | Typical Range |
|---|---|
| Advance size | $25K–$10M |
| Revenue share | 1–12% of monthly revenue |
| Repayment cap | 1.2x–1.6x of advance |
| Minimum revenue | $15K–$200K MRR (varies by provider) |
| Funding speed | 24 hours to 2 weeks |
The real cost comparison: This is where founders often get confused. The "annualized" cost of RBF looks expensive when you run it out as an APR — often 15–30% annually. But that comparison is misleading for three reasons. First, equity is far more expensive if you're actually going to build a valuable business. Giving up 10% of your company at $5M valuation for $500K is "free" money until you exit at $50M and realize you gave away $5M for that $500K. Second, RBF has no option value for the lender — they can't keep upside. Equity has massive option value. Third, for many companies, the alternative isn't VC — it's no capital at all or very expensive working capital loans.
RBF works best when:
RBF is the wrong choice when:
One underrated use case: RBF as a bridge. You're six months from a Series A but need capital to accelerate growth metrics. Instead of taking a dilutive bridge round, you take RBF, hit the metrics, raise equity at a much better valuation. The RBF cost of 1.4x over that period is trivial compared to the valuation uplift you captured.
Y Combinator introduced the Simple Agreement for Future Equity (SAFE) in 2013, and it genuinely changed early-stage fundraising. The original SAFE was elegant: no interest rate, no maturity date, no monthly payments. Just a promise that the investor would get equity at a discount when you eventually raised a priced round.
The landscape has evolved significantly. Here's what you need to know in 2026.
Post-Money SAFEs (the current standard)
YC updated the SAFE template to post-money mechanics in 2018, and this change matters more than most founders realize. Pre-money SAFEs calculated dilution based on the pre-money valuation, meaning every SAFE investor diluted each other as more SAFEs were issued. Post-money SAFEs calculate ownership at the time of issuance — your investor knows exactly what percentage they're getting at that cap.
This sounds founder-unfriendly, and in some ways it is. Post-money SAFEs mean that dilution from the SAFE round falls entirely on the founders (and any employee option pool). The SAFE investors' percentages are locked in. So if you sell $1M of SAFEs on $10M post-money cap, that's 10% gone before you raise the Series A — and the Series A dilutes you, not those SAFE investors.
Implication: Be conservative about how many SAFEs you sell before a priced round. The math compounds quickly, and founders often end up with much less than they expected after accounting for the SAFE overhang, the Series A dilution, and the option pool expansion.
You can download the current YC SAFE templates directly from YC's website. They're free, lawyer-reviewed, and widely accepted. Use them. Don't pay a lawyer to draft a custom instrument when the standard works fine at the seed stage.
Rolling Closes
A rolling close means you don't wait for a single target amount before you start cashing checks. As investors commit, you close their SAFEs and take the money. This is now the norm for pre-seed and seed, not the exception.
Why it matters: Cash runway is everything. Every week you're in fundraising without cash is a week you're not building. Rolling closes let you get to work sooner, extend runway, and build credibility with later investors ("we've already closed $400K, bringing this to $750K total"). The psychological momentum of a partially-filled round is a real fundraising asset.
Mechanics: Set a minimum close — usually $250K–$500K for pre-seed — before you formally announce the round. Once you hit that, announce it publicly and continue raising to your target. Investors who come in later are buying into a company that's already building, which makes the yes/no decision easier for them.
MFN Clauses (Most Favored Nation)
MFN clauses appear in uncapped SAFEs — those issued without a valuation cap. The MFN clause says: if you later issue SAFEs to other investors at more favorable terms (a cap, a bigger discount), those terms automatically apply to the MFN investor too.
Who uses uncapped SAFEs with MFN? Early-stage angels who believe in the founder but don't have enough information to set a cap. It's a way to participate without setting valuation — they'll effectively get whatever terms the next investors negotiate.
Watch out: MFN clauses can create administrative headaches. If you raise an uncapped MFN SAFE early and then raise a capped SAFE six months later, you need to give the MFN investor the capped terms. Track these carefully. One spreadsheet, one source of truth.
Valuation Caps: Where to Set Them in 2026
The question I get most often: "What cap should I use?" The honest answer is that it depends on your market, traction, and who you're talking to. But I can give you a framework.
In the current market, reasonable pre-seed caps (pre-product or early product) tend to fall in the $3M–$8M range for most sectors. Seed caps (post-launch, early revenue) tend to fall in the $8M–$15M range. If you're in a hot sector — AI infrastructure, defense tech, biotech with strong IP — you can push higher. But the days of raising pre-revenue seed rounds at $20M caps as a default are gone for most founders.
The danger of setting your cap too high: You make it harder to close your seed round (sophisticated angels and micro-VCs will pass), and you set a valuation anchor that your Series A has to beat. If you raise at a $15M cap and your business hasn't dramatically grown by the time you go to raise a Series A, you're in a tough spot — either take a flat or down round, or stay stuck on SAFEs.
Pro-Rata Rights
Standard SAFEs include pro-rata rights — investors can participate in future rounds to maintain their ownership percentage. This matters for angels and small funds who want to stay in your company. Understand what you're giving when you grant pro-rata: if you have ten seed investors all with pro-rata, you're leaving very little of your Series A for new money. Negotiate this carefully, or at minimum cap pro-rata participation at a percentage of the new round.
The angel investing landscape has been through its own revolution, driven largely by platforms like AngelList, Republic, and Wefunder.
How Angel Syndicates Work
A syndicate is a lead angel — someone with reputation, deal flow, and a network — who pools capital from a group of limited partners (other angels, small family offices) to write checks larger than any individual could. The lead typically invests their own capital, takes 20% carry on profits, and charges a nominal management fee.
For founders, this is excellent news. You negotiate with one lead who speaks for the group. The check is bigger than you'd get from a solo angel. The lead has skin in the game. And you get a network of 20–50 smaller investors who all have an incentive to help you succeed.
Typical syndicate mechanics:
How to find syndicates: AngelList Syndicates is the largest platform. Search for leads who specialize in your sector. Most active leads post about their portfolio and thesis publicly. Cold outreach to syndicate leads with a warm email (mutual connection, specific reason you're reaching out) converts surprisingly well because they're always looking for deals to put in front of their LPs.
Micro-Funds (under $50M AUM)
The proliferation of sub-$50M funds has been one of the most meaningful changes to the early-stage ecosystem. These are typically solo GPs or two-person partnerships who raised a small fund, usually from their own networks. They write $50K–$500K checks and often specialize by sector, geography, or founder type.
Advantages of micro-VCs for founders:
How to find them: Signal by NFX is the best database of investors by stage and sector. Crunchbase and PitchBook also have good coverage. Look at who's invested in companies at your stage in your sector — those are your targets.
Republic and Regulation CF
Republic operates under Regulation Crowdfunding, which allows non-accredited investors to participate in private company investments. You can raise up to $5M per year this way.
This isn't the right channel for most startups — the process is more involved than a traditional round, you're managing a large number of small investors, and the signal it sends to institutional investors is ambiguous. But for consumer brands with strong community, mission-driven companies, and founders with large followings, it can be genuinely powerful. Investors become customers and advocates. The raise itself is a marketing event.
If you go this route, plan for 60–90 days of prep and execution. A successful Republic raise requires marketing investment — it's not passive. You need an audience to convert, not just a product.
I'll say what the VC-obsessed startup media rarely admits: customer money is the cheapest capital in existence. It's free, it's non-dilutive, it validates your product, and it makes you build differently — which is almost always better.
Every dollar you raise from customers before you raise from investors is a dollar of leverage. If you go to raise a seed round with $30K MRR and 12 months of growth data, you will get a dramatically better valuation and better terms than a competitor pitching the same idea with a prototype. The traction is the thesis.
Pre-Sales and Letters of Intent
For B2B companies especially, pre-sales are underutilized. Before you build, sell. Get a pilot contract. Get a letter of intent. Get someone to hand you a check with a commitment to use your software when it's built.
This does three things: validates that someone will actually pay for what you're making, gives you cash to build with, and creates social proof that accelerates your next conversation.
The objection I always hear: "Our product isn't built yet, how can we sell it?" The answer: You're not selling a product. You're selling a vision and a commitment. Frame it as a design partnership — they get access, input into the roadmap, and heavily discounted pricing in exchange for the early bet on you. Many enterprise buyers actively value being early partners to new tools.
Annual Contracts Upfront
If you're a SaaS company charging monthly, switch to annual pricing with a meaningful discount — typically 2 months free (17% discount). Then figure out how to collect that annual contract upfront.
This is a capital efficiency game-changer. Instead of $2,500/month, you collect $25,000 at the beginning of the year. That cash is on your balance sheet, earning you time and optionality. Your MRR-to-ARR collection ratio improves dramatically, and your cash position looks nothing like your revenue run rate would suggest.
Capchase, Pipe, and other RBF providers will also advance against these annual contracts, so you can layer in non-dilutive capital on top if you need it.
Design Partnerships
For enterprise or technical products, design partnerships are a formal version of the pre-sale model. You find 3–5 companies willing to co-develop the product with you — they provide requirements, feedback, access to their team and data, and in return they get a custom-built solution at zero or minimal cost. You get the product, the case study, and in many cases a paid contract when the partnership phase ends.
This is how many of the most successful B2B SaaS companies were built. The first few customers weren't customers at all — they were co-developers. The product that comes out of this process is dramatically better, and the sales motion for customers 6–50 is much easier because you have real proof from companies that look like them.
When Bootstrapping Doesn't Work
Bootstrapping is not viable for every model. If your market requires massive upfront infrastructure, your cost of customer acquisition requires capital before you can get to payback period, or you're in a category where your competitor is flush and going to outspend you — you probably need outside capital. Knowing when bootstrapping is a rational choice and when it's a rationalization for avoiding fundraising is one of the most important honest conversations you can have with yourself.
There's a class of capital that founders systematically underuse: grants, credits, competitions, and government programs. This money is non-dilutive, relatively plentiful, and often ignored because it requires more effort than a VC intro.
NSF SBIR/STTR (United States)
The Small Business Innovation Research (SBIR) program is a federal grant program across 11 agencies — NSF, NIH, DoD, DOE, and others. Phase I grants are typically $275K. Phase II grants can reach $1.75M. Total SBIR funding in the US exceeds $4B annually.
The catch: The application process is real work. A Phase I proposal takes 3–8 weeks to write properly. The review cycle can take 6 months. Not every startup can get there — you need to be doing genuine R&D with some scientific or technical risk. But if you qualify (deep tech, biotech, climate tech, advanced manufacturing, AI research), this is essentially free money. The government is not asking for equity or a board seat.
The strategy most successful applicants use: Find a program officer at the relevant agency whose portfolio overlaps with your work. Have a conversation before you apply. Program officers can't guarantee funding, but they can tell you whether your project fits the program's priorities, which dramatically increases your hit rate.
Cloud Credits
Every major cloud provider runs a startup program:
These are not trivial amounts. If you're building a cloud-native product and burning $10K–$30K/month on infrastructure, $200K in credits is 7–20 months of free runway. Stack these aggressively — there's no rule against having all three.
Accelerators (the good ones)
Some accelerator programs provide meaningful capital in addition to the network:
The non-obvious insight about accelerators: The money often matters less than the forcing function. Being in a cohort with a Demo Day deadline is a remarkably effective way to compress 18 months of progress into 3. If you're a founder who works well under structure and accountability, an accelerator cohort can be the best decision you make.
Government Programs Globally
If you're not in the US, the landscape is rich:
Many founders don't access these because they require paperwork. That is a bad reason to leave free money on the table. Hire a grants consultant on a success fee (typically 5–10% of the grant amount, paid only if you win) and let them handle the heavy lifting.
The right funding path is not universal. Here's a framework I actually use when talking to founders:
What is your market size?
├── < $500M TAM
│ ├── Consider: Bootstrapping, RBF, grants
│ └── VC is probably the wrong tool
└── $500M+ TAM
├── Do you need capital before revenue?
│ ├── Yes → VC or angel round
│ └── No → Start with revenue, then decide
└── Do you want to maintain control?
├── Yes → Bootstrap, RBF, angels (small checks)
└── No → VC (optimize for speed and scale)More specifically, ask yourself these five questions:
1. What's my actual TAM, and is it winner-take-all? If you're building in a niche B2B market that caps at $200M, VC math doesn't work. Go RBF or bootstrap. If you're building in a market that looks like it could be $10B in 10 years and network effects matter, VC is legitimate.
2. Do I need capital before I can generate revenue? Some businesses require capital before any revenue is possible — biotech, hardware, marketplace chicken-and-egg problems. Others can generate revenue day one. If you're the latter, use revenue as your first capital source.
3. What's my burn multiple? Burn multiple = net burn / net new ARR. If you're burning $200K/month and adding $100K in net new ARR, your burn multiple is 2x — that's high. Investors in 2026 want to see burn multiples below 1.5x at seed, sub-1x by Series A. If your business model inherently produces high burn multiples (heavy enterprise sales cycles, long R&D to revenue timelines), have a clear articulation of when it normalizes.
4. What do I actually want? This is the question founders skip. Do you want to run this company for the next 15 years and build something enduring, even if it grows slowly? Do you want to go for the big outcome and are okay with a 70% chance of failure? Do you want liquidity in 5 years? Be honest with yourself — the funding path should serve your goals, not the investor's.
5. How long can I fund myself? The cheapest round is the one you don't need. If you can extend runway 6 months by cutting burn, that 6 months might be worth $1M in valuation. Runway is optionality, and optionality is everything.
The mechanics of pitching have changed meaningfully. What worked in 2021 won't work today.
What Investors Actually Care About Now
In 2021, the checklist was: large market, fast growth, strong team. Revenue optional. Profitability irrelevant. Today, the checklist has expanded:
The Anti-Pitch Deck
The best pitch decks I've seen recently are more memo than presentation. Not a 15-slide deck with big fonts and stock photos. A dense, data-rich document that shows you understand your business deeply. Think Bezos's narrative memos, not McKinsey slides.
Structure that works:
What to Do Before You Send the First Email
Build your list of target investors before you do anything else. You want 60–80 names. Not every VC in existence — 60–80 people who have actually invested in your category, stage, and geography in the last 24 months. PitchBook, Crunchbase, and Signal by NFX will give you this data. Then sort by warmth of connection — who do you know, who knows them, what mutual portfolio companies do you share?
Start with your warmest connections. The first term sheet is the hardest. Once you have one, everything gets easier — investors have FOMO and you have leverage.
The Fundraising Narrative
Every successful raise has a narrative, not just data. The narrative is the story of inevitability — why this market is going to be huge, why you're the team that's going to win it, and why now is the right moment to bet on this.
The "why now" is the one founders most often butcher. The best answers connect to recent platform shifts or regulatory changes that make the problem newly solvable or newly important. Bad answers: "the market is big and growing." That's not why now. Good answer: "Large language models have made it possible to automate this 40-hour-per-week task at 1/10th the cost of a human, which means for the first time the unit economics work for SMBs, not just enterprises."
Follow-Up and the Close
The hardest part of fundraising isn't getting meetings — it's managing the process through to a close. Most deals die in the middle, not at the start. You'll get lots of "we're interested, let's keep talking" that never converts.
The trick: create urgency without lying. If you have a term sheet, you can truthfully say you have a timeline. If you're running a rolling close and have real momentum, share it. If a well-known investor has just committed, mention it. Social proof and urgency are the two most reliable variables in getting a "yes" across the line.
Fundraising is a sales process. Treat it like one. Have a CRM. Track every conversation. Send follow-ups within 24 hours. Always have a next step. Never go dark on a prospect who's showing genuine interest.
Q: Should I use a SAFE or a priced round at seed?
Almost always a SAFE for pre-seed and early seed. SAFEs are faster to close (no legal negotiation needed if you're using standard YC documents), cheaper (less legal fees), and flexible (rolling closes). Priced rounds require lead investor negotiation, board seats, protective provisions, and often a 60–90 day process. The exception: if you're raising $3M+ at seed and have multiple institutional investors involved, a priced round sometimes makes more sense for everyone's clarity on ownership.
Q: What's the minimum revenue I need to raise a seed round in 2026?
There's no universal answer, but here's a rough benchmark: Pre-seed (under $1M raise) — you can often raise on team and vision with early user traction. Seed ($1M–$3M) — $10K–$50K MRR is the current expectation for many funds, though AI companies sometimes raise earlier on compelling demos and architecture. Series A ($3M–$10M) — $100K–$300K MRR with 18–24 months of data.
Q: Is revenue-based financing dilutive?
No. RBF is debt, not equity. You're giving up future revenue, not ownership. The cost is the repayment multiple (typically 1.3x–1.5x), which you can think of as interest. RBF does not appear on your cap table.
Q: Can I stack multiple funding types?
Yes, and you often should. Common combinations: Angel round (SAFEs) + AWS credits + SBIR grant. VC round + Capchase advance against ARR. Bootstrapped revenue + RBF for growth capital. Just make sure your investor documents don't have restrictions on additional debt — check the covenants.
Q: How do I know if my valuation cap is set correctly?
The market tells you within a few weeks. If you're getting lots of passes on the valuation before investors have even heard the full pitch, it's probably too high. If you're closing every check in the first meeting, you probably set it too low. The right cap gets you closes from serious investors but involves some real negotiation. Talk to 5–10 founders in adjacent spaces who recently raised to calibrate before you set your cap publicly.
Q: How much equity should I expect to give up at seed?
At pre-seed (under $1M), expect 10–20% if you're raising on team/vision. At seed ($1M–$3M), expect 15–25% for the full round, depending on how hot the deal is. These numbers assume standard post-money SAFEs. If you're doing a priced round, add another 10–15% for a 10% option pool refresh that investors will typically require.
Q: What happens if I raise a bunch of SAFEs and then the Series A doesn't happen?
This is the SAFE trap that many founders are in right now. SAFEs convert at a priced round — but if no priced round happens, the SAFEs technically sit in limbo. Some SAFEs have a maturity date (5 years is common), after which they convert to equity at the cap. Others don't convert at all until an equity financing happens. Check your specific documents. The practical answer: if you raise significant SAFE capital and the business doesn't grow fast enough for a Series A, you'll need to either create a liquidity event (acquisition), do a priced seed extension, or have a difficult conversation with investors about options. Know this before you sign.
Q: What's the biggest mistake founders make when fundraising?
Waiting too long to start. Fundraising takes twice as long as you think. Most founders start the process when they're down to 4–5 months of runway, which means they're in a weak position — any investor can see the pressure. Start fundraising with 9–12 months of runway. You'll negotiate better terms, have more optionality, and be able to walk away from bad deals. The best fundraise is the one where you don't actually need the money right now.
The fundraising landscape in 2026 is more complex than it's ever been, and that's actually good news for founders who take the time to understand it. There's no single path. The right answer depends on your market, your business model, your personal goals, and your current stage. Use this guide as a map, not a prescription.
The one thing that hasn't changed: the best fundraising strategy is building something people genuinely want, generating revenue from it as fast as possible, and letting the traction tell the story. Every other tactic in this guide exists to support that core truth, not replace it.
Udit Goenka is a founder and product builder. He writes about startups, product strategy, and the mechanics of building companies at udit.co.
February 2026 saw AI companies raise $189B, more than all of 2025 combined. Here's what the numbers actually mean.
Rowspace exits stealth with $50M from Sequoia and Emergence Capital, targeting private equity firms drowning in deal docs and fragmented data — already live at top PE firms managing over $100 billion in AUM.
February 2026 shattered all venture capital records with $189 billion deployed globally, 90% flowing into AI companies led by OpenAI's $110B round, Anthropic's $30B, and Waymo's $16B.